Recent advancements in understanding the genetics and pathogenic mechanisms of Alzheimer’s disease have led to better preclinical detection and the development of disease-modifying treatments. Blood-based biomarkers now allow early identification and monitoring of therapeutic effects, while emerging therapies like gene editing, enzyme modulators, and inflammatory receptor antagonists are undergoing clinical trials. Although current treatments are limited to symptom management, progress is being made in predicting the disease onset and exploring preventative strategies.

To read the full article, click here: Current Developments in Alzheimer’s Disease – The American Journal of Medicine